Settlement clears way for Lilly to launch once-a-day insulin
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
John Lechleiter, CEO of Eli Lilly and Co., said the company remained confident about its drug pipeline even after it weathered a string of failed clinical trials.
Eugene White, the president of Martin University, had become restless in retirement when the opportunity to lead the struggling black liberal arts college surfaced.
Paul Baltzell, the state of Indiana's chief information officer, is excited about the power of data analytics to improve the effectiveness of government.
Simon Property Group executive David Contis says technology will enhance, not kill, bricks-and-mortar retail.
Crystal Grave, CEO of the event-planning search engine Snappening, gained new perspective on the Indy tech community after spending time in Silicon Valley.
Hillary Clinton said she would give close scrutiny to health-insurance industry mergers like those proposed this year by Anthem Inc. and Aetna Inc., part of the Democratic presidential candidate’s latest policy plans.
It looks like Eli Lilly and Co. finally has a drug that can replace its former stars Zyprexa and Cymbalta. The most bullish analysts think Jardiance can surpass those $5 billion-a-year blockbusters.
Requiring a delicate balance of whimsy, theatrics and sincerity, the musical has its problems. But it can thrive when planted in the proper theater and given appropriate watering.
GIPC birthday brought together city leaders who knew how to achieve, in spite of politics.
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.
Near-zero interest rates were supposed to pep up the economy. Six years and 10 months later, economic growth has been positive, but anemic. The unemployment rate has fallen to 5.1 percent, but labor force participation rates are at record lows and full-time jobs are hard to find.
A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.
Minneapolis-based Onward Investors LLC has purchased the 93-year-old building on East Washington Street and is planning a major renovation. The new owner hopes to attract a restaurant to the first floor.
Indianapolis-based American Senior Communities, which was raided by federal agents Tuesday, said it will fully comply with a government investigation.
The Central Indiana Corporate Partnership wants the city to improve streets, walkways and other infrastructure around the 170-acre project north of the IUPUI campus, designed to attract high-tech businesses and workers.
The 70-million-electron-volt cyclotron is being installed at Zevacor Molecular’s headquarters and production facility on Bergen Boulevard near Hamilton Town Center.
Absent any great choices, I’m daydreaming about who would get my vote.
Prices set below what a free-exchange market would determine result in shortages. Above-market prices produce unsold piles of surpluses.